Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder

Betsy D. Kennard, Graham J. Emslie, Taryn L. Mayes, Jeanne Nightingale-Teresi, Paul A. Nakonezny, Jennifer L. Hughes, Jessica M. Jones, Rongrong Tao, Sunita M. Stewart, Robin B. Jarrett

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Objective: We present results of a feasibility test of a sequential treatment strategy using continuation phase cognitive-behavioral therapy (CBT) to prevent relapse in youths with major depressive disorder (MDD) who have responded to acute phase pharmacotherapy. Method: Forty-six youths (ages 11-18 years) who had responded to 12 weeks of treatment with fluoxetine were randomized to receive either 6 months of continued antidepressant medication management (MM) or antidepressant MM plus relapse prevention CBT (MM+CBT). Primary outcome was time to relapse, defined as a Childhood Depression Rating Scale-Revised score of 40 or higher and 2 weeks of symptom worsening or clinical deterioration warranting alteration of treatment to prevent full relapse. Results: Cox proportional hazards regression, adjusting for depression severity at randomization and for the hazard of relapsing by age across the trial, revealed that participants in the MM treatment group had a significantly greater risk for relapse than those in the MM+CBT treatment group (hazard ratio = 8.80; 95% confidence interval 1.01-76.89; χ2 = 3.86, p = .049) during 6 months of continuation treatment. In addition, patient satisfaction was significantly higher in the MM+CBT group. No differences were found between the two treatment groups on attrition rate, serious adverse events, and overall global functioning. Conclusions: These preliminary results suggest that continuation phase CBT reduces the risk for relapse by eightfold compared with pharmacotherapy responders who received antidepressant medication alone during the 6-month continuation phase.

Original languageEnglish (US)
Pages (from-to)1395-1404
Number of pages10
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume47
Issue number12
DOIs
StatePublished - Dec 2008

Fingerprint

Major Depressive Disorder
Cognitive Therapy
Pediatrics
Recurrence
Drug Therapy
Antidepressive Agents
Therapeutics
Depression
Fluoxetine
Random Allocation
Secondary Prevention
Patient Satisfaction
Confidence Intervals

Keywords

  • CBT
  • Depression
  • Relapse prevention
  • Sequential treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

@article{05e89d8f974941f5bf124ce03ea25f87,
title = "Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder",
abstract = "Objective: We present results of a feasibility test of a sequential treatment strategy using continuation phase cognitive-behavioral therapy (CBT) to prevent relapse in youths with major depressive disorder (MDD) who have responded to acute phase pharmacotherapy. Method: Forty-six youths (ages 11-18 years) who had responded to 12 weeks of treatment with fluoxetine were randomized to receive either 6 months of continued antidepressant medication management (MM) or antidepressant MM plus relapse prevention CBT (MM+CBT). Primary outcome was time to relapse, defined as a Childhood Depression Rating Scale-Revised score of 40 or higher and 2 weeks of symptom worsening or clinical deterioration warranting alteration of treatment to prevent full relapse. Results: Cox proportional hazards regression, adjusting for depression severity at randomization and for the hazard of relapsing by age across the trial, revealed that participants in the MM treatment group had a significantly greater risk for relapse than those in the MM+CBT treatment group (hazard ratio = 8.80; 95{\%} confidence interval 1.01-76.89; χ2 = 3.86, p = .049) during 6 months of continuation treatment. In addition, patient satisfaction was significantly higher in the MM+CBT group. No differences were found between the two treatment groups on attrition rate, serious adverse events, and overall global functioning. Conclusions: These preliminary results suggest that continuation phase CBT reduces the risk for relapse by eightfold compared with pharmacotherapy responders who received antidepressant medication alone during the 6-month continuation phase.",
keywords = "CBT, Depression, Relapse prevention, Sequential treatment",
author = "Kennard, {Betsy D.} and Emslie, {Graham J.} and Mayes, {Taryn L.} and Jeanne Nightingale-Teresi and Nakonezny, {Paul A.} and Hughes, {Jennifer L.} and Jones, {Jessica M.} and Rongrong Tao and Stewart, {Sunita M.} and Jarrett, {Robin B.}",
year = "2008",
month = "12",
doi = "10.1097/CHI.0b013e31818914a1",
language = "English (US)",
volume = "47",
pages = "1395--1404",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder

AU - Kennard, Betsy D.

AU - Emslie, Graham J.

AU - Mayes, Taryn L.

AU - Nightingale-Teresi, Jeanne

AU - Nakonezny, Paul A.

AU - Hughes, Jennifer L.

AU - Jones, Jessica M.

AU - Tao, Rongrong

AU - Stewart, Sunita M.

AU - Jarrett, Robin B.

PY - 2008/12

Y1 - 2008/12

N2 - Objective: We present results of a feasibility test of a sequential treatment strategy using continuation phase cognitive-behavioral therapy (CBT) to prevent relapse in youths with major depressive disorder (MDD) who have responded to acute phase pharmacotherapy. Method: Forty-six youths (ages 11-18 years) who had responded to 12 weeks of treatment with fluoxetine were randomized to receive either 6 months of continued antidepressant medication management (MM) or antidepressant MM plus relapse prevention CBT (MM+CBT). Primary outcome was time to relapse, defined as a Childhood Depression Rating Scale-Revised score of 40 or higher and 2 weeks of symptom worsening or clinical deterioration warranting alteration of treatment to prevent full relapse. Results: Cox proportional hazards regression, adjusting for depression severity at randomization and for the hazard of relapsing by age across the trial, revealed that participants in the MM treatment group had a significantly greater risk for relapse than those in the MM+CBT treatment group (hazard ratio = 8.80; 95% confidence interval 1.01-76.89; χ2 = 3.86, p = .049) during 6 months of continuation treatment. In addition, patient satisfaction was significantly higher in the MM+CBT group. No differences were found between the two treatment groups on attrition rate, serious adverse events, and overall global functioning. Conclusions: These preliminary results suggest that continuation phase CBT reduces the risk for relapse by eightfold compared with pharmacotherapy responders who received antidepressant medication alone during the 6-month continuation phase.

AB - Objective: We present results of a feasibility test of a sequential treatment strategy using continuation phase cognitive-behavioral therapy (CBT) to prevent relapse in youths with major depressive disorder (MDD) who have responded to acute phase pharmacotherapy. Method: Forty-six youths (ages 11-18 years) who had responded to 12 weeks of treatment with fluoxetine were randomized to receive either 6 months of continued antidepressant medication management (MM) or antidepressant MM plus relapse prevention CBT (MM+CBT). Primary outcome was time to relapse, defined as a Childhood Depression Rating Scale-Revised score of 40 or higher and 2 weeks of symptom worsening or clinical deterioration warranting alteration of treatment to prevent full relapse. Results: Cox proportional hazards regression, adjusting for depression severity at randomization and for the hazard of relapsing by age across the trial, revealed that participants in the MM treatment group had a significantly greater risk for relapse than those in the MM+CBT treatment group (hazard ratio = 8.80; 95% confidence interval 1.01-76.89; χ2 = 3.86, p = .049) during 6 months of continuation treatment. In addition, patient satisfaction was significantly higher in the MM+CBT group. No differences were found between the two treatment groups on attrition rate, serious adverse events, and overall global functioning. Conclusions: These preliminary results suggest that continuation phase CBT reduces the risk for relapse by eightfold compared with pharmacotherapy responders who received antidepressant medication alone during the 6-month continuation phase.

KW - CBT

KW - Depression

KW - Relapse prevention

KW - Sequential treatment

UR - http://www.scopus.com/inward/record.url?scp=57749193077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749193077&partnerID=8YFLogxK

U2 - 10.1097/CHI.0b013e31818914a1

DO - 10.1097/CHI.0b013e31818914a1

M3 - Article

VL - 47

SP - 1395

EP - 1404

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 12

ER -